MIDBA: A New Regulatory Approach To Clinical Device Bridging

Drug-device combination products frequently undergo device updates during development, creating regulatory challenges when clinical data were generated with an earlier version. A risk-based approach to clinical device bridging can help sponsors evaluate whether additional human factors, performance, or clinical evidence is needed to support a device change without unnecessarily delaying development timelines.

Key considerations include assessing the impact of design modifications on user interaction, product performance, and overall patient safety while aligning with evolving regulatory expectations. Strategic planning, early evidence generation, and clear documentation can strengthen submissions and reduce uncertainty during regulatory review. For teams developing injectable therapies and other combination products, understanding modern bridging principles is becoming increasingly important as device innovation accelerates.

Read the full article to learn how emerging regulatory thinking may streamline development while maintaining confidence in safety and effectiveness.